RecruitingPhase 4NCT03933384

Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial

Sponsor

Taichung Veterans General Hospital

Enrollment

140 participants

Start Date

Aug 19, 2019

Study Type

INTERVENTIONAL

Conditions

Hepatitis B Viral Hepatitis

Summary

To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.

Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Entecavir and a drug called Tenofovir alafenamide for people with hepatitis b and viral hepatitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 20 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.